Oncotarget

Research Papers:

Preliminary quantitative proteomics analysis in chronic and latent Keshan disease by iTRAQ labeling approach

Yuxiao Sun, Chuanyu Gao _, Xianqing Wang and Yuhao Liu

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:105761-105774. https://doi.org/10.18632/oncotarget.22397

Metrics: PDF 1343 views  |   HTML 2179 views  |   ?  


Abstract

Yuxiao Sun1,2, Chuanyu Gao1,2, Xianqing Wang1,2 and Yuhao Liu1,2

1Department of Cardiology, Zhengzhou University, People’s Hospital, Zhengzhou, Henan 450003, PR China

2Department of Cardiology, Henan Provincial People’s Hospital, Zhengzhou, Henan 450003, PR China

Correspondence to:

Chuanyu Gao, email: [email protected]

Keywords: Keshan disease; iTRAQ; proteomics; DEPs; biomarker

Received: August 12, 2017    Accepted: October 05, 2017    Published: November 11, 2017

ABSTRACT

Keshan disease is a congestive cardiomyopathy. Dietary selenium deficiency combined with additional stressors are recognized to cause the cardiomyopathies. In this study, clinical condition of individuals with different subtypes including chronic and latent were analyzed. ECG abnormalities, chest radiography, echocardiography and blood selenium concentration were assessed. Subsequently, in effort to uncover proteins that were reliably changed in patients, isobaric tags for absolute and relative quantitation technology was applied. Bioinformatics analysis of the differentially expressed proteins were performed by means of Gene Ontology classification, KEGG pathway, and Ingenuity Pathway Analysis. ELISA experiment was used to detect the interesting proteins. As a result, chronic patients showed more EGC abnormalities compared to Latent. All patients had low blood selenium level. Proteomics data revealed 28 differentially expressed proteins. By ELISA variation, LGALS3BP was increased in chronic patients. PZP was elevated specially in latent patients. The above results might be beneficial for further biomarkers discovery and Keshan disease pathological mechanism study.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22397